{"eventGroups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"EG000","otherNumAffected":34,"otherNumAtRisk":41,"seriousNumAffected":8,"seriousNumAtRisk":41,"title":"Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)"},{"description":"Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"EG001","otherNumAffected":20,"otherNumAtRisk":44,"seriousNumAffected":5,"seriousNumAtRisk":44,"title":"Arm II (TBI, Transplant, GVHD Prophylaxis)"}],"frequencyThreshold":"0","otherEvents":[{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":41},{"groupId":"EG001","numAffected":10,"numAtRisk":44}],"term":"Blood/Bone marrow"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":41},{"groupId":"EG001","numAffected":5,"numAtRisk":44}],"term":"Cardiovascular"},{"organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"Dermatology/Skin"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":41},{"groupId":"EG001","numAffected":3,"numAtRisk":44}],"term":"Gastrointestinal"},{"organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"Hemorrhage"},{"organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":41},{"groupId":"EG001","numAffected":3,"numAtRisk":44}],"term":"Hepatic"},{"organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"Metabolic/Laboratory"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"Pain"},{"organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":41},{"groupId":"EG001","numAffected":4,"numAtRisk":44}],"term":"Pulmonary"},{"organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"Renal/Genitourinary"},{"organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"Second Malignancy"}],"seriousEvents":[{"organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"respiratory failure"},{"organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"seizure"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"pericardial effusion"},{"organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"thrombosis"},{"organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"Bactrim anaphylaxis"},{"organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":2,"numAtRisk":44}],"term":"Graft versus host disease with infection and organ failure"},{"organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":41},{"groupId":"EG001","numAffected":1,"numAtRisk":44}],"term":"subdural hematoma"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":41},{"groupId":"EG001","numAffected":0,"numAtRisk":44}],"term":"sepsis"}]}